Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Kendall

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Coronary Artery Disease|December 2, 2005
Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitusGregg D Simonson, David M Kendall
Diabetes Technology & Therapeutics|June 28, 2006
Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetesDavid M Kendall, Dennis Kim, David Maggs
The American Journal of Medicine|May 26, 2009
Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical useDavid M Kendall, Robert M Cuddihy, Richard M Bergenstal
Expert Opinion on Pharmacotherapy|October 6, 2006
Management of Type 2 diabetes: the role of incretin mimeticsAnthony H Stonehouse, John H Holcombe, David M Kendall
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 3, 2004
Insulin resistance syndromeVivian A Fonseca, David M Kendall, Burton E Sobel, et al.
Nature Reviews. Endocrinology|February 23, 2010
Diabetes: Strategies to prevent the type 2 diabetes mellitus epidemicR Paul Robertson, David M Kendall, Elizabeth R Seaquist
Diabetes Care|August 23, 2014
Frederick C. Goetz, MD: a profile of the intersection among science, the fine arts, and educationByron J Hoogwerf, David M Kendall, Elizabeth R Seaquist
European Journal of Internal Medicine|July 8, 2009
Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical useDavid M Kendall, Robert M Cuddihy, Richard M Bergenstal
The American Journal of Medicine|April 6, 2010
Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medicationsRichard M Bergenstal, Clifford J Bailey, David M Kendall
Diabetes|September 26, 2013
Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604Robert J Heine, Haoda Fu, David M Kendall, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Coronary Artery Disease|December 2, 2005
Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitusGregg D Simonson, David M Kendall
Diabetes Technology & Therapeutics|June 28, 2006
Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetesDavid M Kendall, Dennis Kim, David Maggs
The American Journal of Medicine|May 26, 2009
Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical useDavid M Kendall, Robert M Cuddihy, Richard M Bergenstal
Expert Opinion on Pharmacotherapy|October 6, 2006
Management of Type 2 diabetes: the role of incretin mimeticsAnthony H Stonehouse, John H Holcombe, David M Kendall
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 3, 2004
Insulin resistance syndromeVivian A Fonseca, David M Kendall, Burton E Sobel, et al.
Nature Reviews. Endocrinology|February 23, 2010
Diabetes: Strategies to prevent the type 2 diabetes mellitus epidemicR Paul Robertson, David M Kendall, Elizabeth R Seaquist
Diabetes Care|August 23, 2014
Frederick C. Goetz, MD: a profile of the intersection among science, the fine arts, and educationByron J Hoogwerf, David M Kendall, Elizabeth R Seaquist
European Journal of Internal Medicine|July 8, 2009
Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical useDavid M Kendall, Robert M Cuddihy, Richard M Bergenstal
The American Journal of Medicine|April 6, 2010
Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medicationsRichard M Bergenstal, Clifford J Bailey, David M Kendall
Diabetes|September 26, 2013
Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604Robert J Heine, Haoda Fu, David M Kendall, et al.
Pageof 6